The dementia was caused by Alzheimers disease, dementia with Lewy bodies, frontotemporal dementia, Parkinsons disease with dementia, or vascular dementia. The trial was stopped early for efficacy. Patients treated with pimavanserin had a relapse in 13%, without in 28% (hazard ratio 0.35; 95% CI = 0.17-0.73; p = 0.005). Longer and larger trials are suggested. Controversy
On April 9, 2018, CNN reported that some in the FDA were concerned that Nuplazid was "risky" when it was approved and noted there have been a substantial number of deaths reported by those using the drug. The story further noted that the drug was approved based on a "six-week study of about 200 patients". The FDA began post-market monitoring of the drug to assess the validity of these claims. On September 20, 2018, the FDA stated their review "did not identify any new or unexpected safety findings with Nuplazid, or findings that are inconsistent with the established safety profile currently described in the drug label". Research
Pimavanserin is under development for the treatment of major depressive disorder, schizophrenia, agitation, and psychiatric disorders. As of March 2022, pimavanserin is in phase 3 clinical trials for major depressive disorder and schizophrenia, phase 2 trials for agitation, and phase 1 trials for psychiatric disorders. It was also under development for the treatment of insomnia, drug-induced akathisia, and drug-induced dyskinesia, but development for these indications was discontinued. See also
List of investigational antipsychotics
List of investigational antidepressants
Ketanserin

References
Further reading
McGuire, Donna (May 10, 2017). "New drug can ease Parkinsons psychosis". Chicago Tribune. p. 5 (section 5) – via Newspapers.com.
External links
Nuplazid (pimavanserin) Official Site
Pimanvaserin - AdisInsight